SCHEMBL10118352

SCHEMBL10118352

Cc1ccc(/N=C/c2ccc(/C=N/c3ccc(C)cc3O)cc2)c(O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.59
MAPT P10636 8/20 0.59
ALDH1A1 P00352 7/20 0.59
GAA P10253 5/20 0.59
POLB P06746 3/20 0.59
ALOX15 P16050 3/20 0.59
HSD17B10 Q99714 3/20 0.59
HTT P42858 5/20 0.51
LMNA P02545 4/20 0.51
MAOA P21397 3/20 0.50
MAOB P27338 3/20 0.50
HPGD P15428 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
THRB P10828 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.47
ALOX12 P18054 1/20 0.47
MPI P34949 1/20 0.47
USP2 O75604 2/20 0.45
TRPA1 O75762 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22366968 0.78 CYP3A4 (0.56) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL30069248 0.78 CYP3A4 (0.56) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL24067974 0.78 CYP3A4 (0.56) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL14431304 0.78 KDM4E (0.48) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL22103735 0.78 MAPT (0.61) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL5406816 0.77 KDM4E (0.65) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL5406815 0.77 KDM4E (0.65) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL31634636 0.76 CYP19A1 (0.40) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL3278219 0.75 TRPA1 (0.52) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL13427227 0.75 MAPT (1.00) KDM4EMAPTALDH1A1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352624-B2 Reducing nonsense-mediated MRNA decay COLD SPRING HARBOR LABORATORY (US) 2022-06-07 US disclosed
US-20200283762-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2020-09-10 US disclosed
EP-3690048-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2020-08-05 EP disclosed
US-10647983-B2 Reducing nonsense-mediated mRNA decay COLD SPRING HARBOR LABORATORY (US) 2020-05-12 US disclosed
US-20170159049-A9 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2017-06-08 US disclosed
US-9598395-B2 Premature-termination-codons readthrough compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-03-21 US disclosed
US-9598395-B2 Premature-termination-codons readthrough compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-03-21 US disclosed
EP-3041958-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2016-07-13 EP disclosed
US-20160194630-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2016-07-07 US disclosed
US-9255088-B2 Premature-termination-codons readthrough compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-02-09 US disclosed
WO-2015035091-A1 REDUCING NONSENSE-MEDIATED MRNA DECAY COLD SPRING HARBOR LABORATORY (US) 2015-03-12 WO disclosed
US-20150051251-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-02-19 US disclosed
US-20150051251-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-02-19 US disclosed
US-20130274283-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-10-17 US disclosed
US-20130274283-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-10-17 US disclosed
WO-2012021707-A2 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274283-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS UPF1, NUDT21, RNGTT KDM4E 2336/4885MAPT 4401/4885ALDH1A1 4427/4885
US-20150051251-A1 PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS UPF1, NUDT21, RNGTT KDM4E 2336/4885MAPT 4401/4885ALDH1A1 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.